Skip to main content

Advertisement

SpringerLink
Log in

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We previously identified a correlation between estrogen receptor alpha (ERα) and the candidate tumour suppressor gene Forkhead Box P1 (FOXP1), whose nuclear protein expression in breast tumours was associated with improved patient survival. However, the expression pattern of FOXP1 in normal breast tissue is more reminiscent of the second receptor, ERβ, which has an emerging role as a tumour suppressor in breast cancer and critically may underlie the ability of some ERα-negative tumours to respond to tamoxifen. In a series of 283 breast cancers, in which ERα-positive tumours were treated with tamoxifen, the nuclear expression of ERβ correlated significantly with ERα (p = 0.004), low-tumour grade (p = 0.008) and nuclear FOXP1 (p = 0.01). High-grade tumours exhibited significantly more cytoplasmic ERβ than the low-grade tumours (p = 0.006). Regression analysis demonstrated that FOXP1 expression was most closely related to nuclear ERβ (p = 0.021). Neither, nuclear or cytoplasmic ERβ expression demonstrated prognostic significance. FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERα, ERβ or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wang B, Weidenfeld J, Lu MM et al (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131(18):4477–4487

    Article  PubMed  CAS  Google Scholar 

  2. Banham AH, Beasley N, Campo E et al (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61(24):8820–8829

    PubMed  CAS  Google Scholar 

  3. Fox SB, Brown P, Han C et al (2004) Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10(10):3521–3527

    Article  PubMed  CAS  Google Scholar 

  4. Bieche I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosomes Cancer 14(4):227–251

    Article  PubMed  CAS  Google Scholar 

  5. Martinez A, Walker RA, Shaw JA et al (2001) Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54(5):300–306

    Article  PubMed  CAS  Google Scholar 

  6. Giatromanolaki A, Koukourakis MI, Sivridis E et al (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19(1):9–16

    Article  PubMed  CAS  Google Scholar 

  7. Banham AH, Boddy J, Launchbury R et al (2007) Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate 67(10):1091–1098

    Article  PubMed  CAS  Google Scholar 

  8. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112

    Article  PubMed  Google Scholar 

  9. Murphy LC, Watson PH (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13(2):327–334

    Article  PubMed  CAS  Google Scholar 

  10. Speirs V, Walker RA (2007) New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 211(5):499–506

    Article  PubMed  CAS  Google Scholar 

  11. Gruvberger-Saal SK, Bendahl PO, Saal LH et al (2007) Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13(7):1987–1994

    Article  PubMed  CAS  Google Scholar 

  12. McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36(2):638–644

    Article  PubMed  CAS  Google Scholar 

  13. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351(9114):1451–1467

  14. Speirs V, Skliris GP, Burdall SE et al (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55(5):371–374

    PubMed  CAS  Google Scholar 

  15. Elston C (1987) Grading of invasive carcinoma of the breast. In: Page D, Anderson T (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 300–311

    Google Scholar 

  16. Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20(3):358–417

    Article  PubMed  CAS  Google Scholar 

  17. Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27):24353–24360

    Article  PubMed  CAS  Google Scholar 

  18. Pajer P, Pecenka V, Kralova J et al (2006) Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 66(1):78–86

    Article  PubMed  CAS  Google Scholar 

  19. Speirs V, Carder PJ, Lane S et al (2004) Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5(3):174–181

    Article  PubMed  CAS  Google Scholar 

  20. Speirs V, Parker M, Green A et al (2006) Progress towards unlocking the secrets of oestrogen receptor beta in breast cancer. Breast Cancer Res 8(Suppl 2):P24

    Article  Google Scholar 

  21. Heldring N, Pike A, Andersson S et al (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87(3):905–931

    Article  PubMed  CAS  Google Scholar 

  22. Skliris GP, Munot K, Bell SM et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213–220

    Article  PubMed  CAS  Google Scholar 

  23. Zhao C, Lam EW, Sunters A et al (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48):7600–7606

    Article  PubMed  CAS  Google Scholar 

  24. Kim SJ, Kim TW, Lee SY et al (2004) CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med 14(2):289–293

    PubMed  CAS  Google Scholar 

  25. Rody A, Holtrich U, Solbach C et al (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12(4):903–916

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by funding from the Breast Cancer Campaign, Cancer Research UK, Tenovus and the Leukaemia Research Fund.

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK

    Gaynor J. Bates, Rosalind Launchbury, Russell D. Leek & Alison H. Banham

  2. Peter MacCallum Cancer Centre, A’Beckett Street, East Melbourne, VIC, 8006, Australia

    Stephen B. Fox

  3. Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK

    Cheng Han & Adrian L. Harris

Authors
  1. Gaynor J. Bates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen B. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosalind Launchbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Russell D. Leek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adrian L. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alison H. Banham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alison H. Banham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bates, G.J., Fox, S.B., Han, C. et al. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas. Breast Cancer Res Treat 111, 453–459 (2008). https://doi.org/10.1007/s10549-007-9812-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9812-4

Keywords

Search

Navigation